FK‑317 is a substituted dihydrobenzoxazine small-molecule antineoplastic agent that induces tumor-selective cytotoxic metabolites in cancer cells, achieving broad-spectrum antitumor efficacy in murine and human xenograft models while avoiding vascular leak syndrome . The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Fk 317 Dihydrobenzoxazine and FR 073317. Its PubChem CID is 121492536.
Fk 317
| CAS No | 102409-92-7 |
|---|---|
| Molecular Formula | C19H21N3O8 |
| Molecular Weight | 419.40 g/mol |
| Synonyms | [(8R,10S,12S)-11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3,5-trien-9-yl] acetate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
FK‑317 is a substituted dihydrobenzoxazine small-molecule antineoplastic agent that induces tumor-selective cytotoxic metabolites in cancer cells, achieving broad-spectrum antitumor efficacy in murine and human xenograft models while avoiding vascular leak syndrome .
The listed CAS number is 102409-92-7.
The listed molecular formula is C19H21N3O8.
The listed molecular weight is 419.40 g/mol.
[(8R,10S,12S)-11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3,5-trien-9-yl] acetate.
The source lists Fk 317 Dihydrobenzoxazine and FR 073317.